BREATHE (B cell receptor evaluation for SARS-coV-2) [COVID-19}
Research type
Research Study
Full title
B cell Receptor Evaluation for Antibodies to proTect Human Exposure to SARS‐CoV‐2
IRAS ID
283039
Contact name
Stephen Jolles
Contact email
Sponsor organisation
University Hospital of Wales
Clinicaltrials.gov Identifier
IRAS 276167, REC approval for general approach - 9th December 2019
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
There are currently no virus-specific treatments or vaccines to protect against COVID-19 infection. Vaccination will play a key role, but using the body’s natural ability to produce protective antibodies can also be a valuable approach. PROJECT BREATHE aims to bring together a coalition of companies, academics, NHS and public sector across the UK and internationally to generate large numbers of doses of therapeutic antibodies against COVID19. In order to be successful, we need to source samples from patients with a range of responses to viral infection. The samples will be used to look at the different antibody responses in different types of patients and find which antibodies are associated with the best response to the disease.\nThis work is being done under an understanding there is no commercial intent and participants are initially providing contributions of resource, reagents and time at their own cost. \n
REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
20/HRA/1885
Date of REC Opinion
20 Apr 2020
REC opinion
Favourable Opinion